Compare HOVR & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | NSPR |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 77.5M |
| IPO Year | N/A | 2009 |
| Metric | HOVR | NSPR |
|---|---|---|
| Price | $1.88 | $1.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $10.33 | $4.00 |
| AVG Volume (30 Days) | ★ 500.2K | 23.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $22.91 |
| Revenue Next Year | N/A | $72.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $1.51 |
| 52 Week High | $4.18 | $3.34 |
| Indicator | HOVR | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 42.23 |
| Support Level | $1.69 | $1.56 |
| Resistance Level | $1.90 | $2.51 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 45.71 | 21.70 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.